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Review

Clinical trials in multiple sclerosis:
potential future trial designs
Navid Manouchehri, Yinan Zhang, Amber Salter, Rehana Z. Hussain, Hans-Peter Hartung,
Bernhard Hemmer, Ralf Linker, Benjamin M. Segal, Gary Cutter and Olaf Stüve

Abstract: Clinical trials of new treatments in multiple sclerosis (MS) currently require large
sample sizes and long durations in order to yield reliable results. The differential responses of
an already heterogeneous population of MS patients to individual disease-modifying therapies
(DMTs) will further complicate future trials. MS trials with smaller samples and faster
outcomes are conceivable through the substitution of current clinical and MRI outcomes with
objectively measureable genomic and proteomic biomarkers. Currently, biomarkers that could
be utilized for diagnosis and monitoring of MS disease activity are in the early validation phase.
The power of single biomarkers or multiple correlated biomarkers to predict prognosis and
response to treatment could initially be compared with currently accepted methods. These
prospectively validated disease biomarkers could then be used to subcategorize the spectrum
of MS patients into a finite number of endophenotypes with demonstrable different molecular
pathogeneses and DMT response profiles. Newly developed DMT could potentially be
assessed within specific endophenotypes and compared with pharmacogenomically relevant
active comparator DMT. This approach may increase the efficiency of MS trials through
homogenization of patient population and minimization of nonresponders in study groups,
providing the potential for the development of targeted therapies.
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Introduction
Clinical trials in multiple sclerosis (MS) have
been the cornerstone of drug development, leading to the introduction of an arsenal of diseasemodifying therapies (DMT) that has provided
neurologists with a range of options for the treatment of MS, thereby improving chances for a
beneficial neurological outcome.1
The ultimate goal of a curative treatment for all
patients with MS has not been achieved. Even
today, with accurate early diagnosis, aggressive
treatment, and vigilant clinical and paraclinical
monitoring for breakthrough disease activity, a
proportion of MS patients inevitably accumulate
neurological disability and transition into a progressive disease course that is currently not
responsive, or only marginally responsive, to
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approved pharmacotherapies. This calls for continued research to better understand the immunopathological phenomena that drive disease
activity, and to develop more effective interventions based on this newly acquired knowledge.
One approach toward understanding the pathogenesis of MS is to investigate therapies targeted
to specific patients in the context of clinical trials.
A major question that remains is whether candidate treatments that do not seem to benefit MS
patients are truly not effective, or whether the
benefits are seen in areas not currently measured.
There is a difference between those patients who
fail based on current measures and those who
may not appear to achieve benefits. Thus, the
design of time-limited and budget-efficient phase
III MS clinical trials faces unprecedented challenges that are due to the nature of the disease,
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the availability of numerous DMTs, and the
standard outcomes used.
The status quo and limitations of current
trial designs
MS heterogeneity
Clinically, MS is a very heterogeneous disease
with regard to age of onset, neurological manifestations, relapse rates, and the rate at which neurological disability accumulates.2,3 Also, the disease
course appears to differ between ethnic and racial
patient populations.4 There is also heterogeneity
in the diversity of pharmacological and immunological candidate putative molecular and cellular
targets.5,6 Consequently, the challenge to identify
the correct pharmacological agent for the correct
patient population during the correct disease
stage can be daunting.
It is currently thought that genetic susceptibility7–10 and environmental risk factors11–15 play a
role in pathophysiology of MS. The extent of
the involvement of specific factors in the initiation and perpetuation of MS disease activity
remains to be elucidated. Presumably, the initiation of MS is not predicated on a singular and
sudden event, but rather a series of genetically
and proteomically permissive and environmentally triggered events that become chronic and
variable. The relative importance and combination of contributing genetic and environmental
risk factors likely drive the variability of disease
phenotypes among MS populations on individual and global scales. A meaningful and clinically significant genetic association for central
nervous system (CNS) autoimmunity among
humans is currently limited to HLADRB1*15:01,
which may also impact disease activity.16 Large
genome-wide or exome screening assays have
not been able to identify other risk alleles that
have a meaningful impact on clinical disease
onset or phenotype.17–19
Given the heterogeneity of clinical disease in
patients with MS, different environmental factors
may be critical in different populations. Globally,
MS incidence varies across macro-geographical
areas,20 and may be modulated by latitude and sun
exposure,21 the degree of urbanization,22 the prevalence of certain infections,23 smoking,24 and other
factors.25,26 Variability in neurological signs, relapse
frequency, and the rate of disease progression
2

results in a wide range of clinical phenotypes from
benign relapsing MS with very limited progression
over decades27–29 to primary progressive MS with
relentless accumulation of disability and premature
death.30–32 The MS spectrum is further complicated by the introduction of subclinical MS, as seen
in radiologically isolated syndromes (RIS)33 and
the concept of MS prodrome.34–37 Differential
treatment responses to DMTs in clinical trials and
post-drug approval also constitute disease heterogeneity.38 This heterogeneity among MS patients
illustrates an unmet need for more individualized
treatment approaches through improved pharmacogenomic methods, which in turn will require
objective molecular categorization of subclasses of
MS patients.
Current problems in the clinical and
paraclinical assessment of MS
Clinical and paraclinical MS has thus far been
examined on a macro-anatomical scale both in
terms of diagnosis and follow up of disease activity. MS is diagnosed when there is overt clinical
disability accompanied by corroborating MRI
abnormalities. Obvious flaws of this approach are
delays in diagnoses and relatively frequent
misdiagnoses.39–41
Current disease phenotypes are mostly based on
clinical characteristics, and magnetic resonance
imaging (MRI) of the brain as the paraclinical
biomarker for further definition of these clinical
phenotypes.42 However, currently utilized clinical
and paraclinical tools for detection and monitoring of MS are limited.
The Expanded Disability Status Scale (EDSS), as
the main clinical scoring scale for MS disability
assessment and estimation of disease progression,
has a skewed reliance on measurable physical disability and primarily reflects ambulation status as
the readout of physical deficits. However, neurological deficits secondary to MS span across functional areas that are not easy to capture, including
cognitive decline, sensory disturbances, and loss
of motor dexterity.43 The EDSS only registers
overt deficits and misses the subtle clinical deteriorations in the course of the disease as it is
inherently limited by the sensitivity of the clinical
examinations that constitute this scale.44 Finally,
the EDSS records clinical information retrospectively, but yields no information on disease
progression.43,45
journals.sagepub.com/home/tan
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Other disability scales, including the Multiple
Sclerosis Functional Composite (MSFC), a
three-part, standardized, quantitative assessment
instrument that was developed to address some of
the problems of the EDSS,46 was criticized by
regulators for the uncertain clinical meaningfulness of the composite measure.
MRI as the main paraclinical assessment method
in MS is also flawed due to its dependence on
relatively large anatomical structural changes
within the CNS. It is very likely that disease progression continues on a micro-level, driven by cellular and molecular events beyond the sensitivity
of MRI.44
Analyses of CSF specimens show oligoclonal
bands (OCBs) in most patients. Composed of
immunoglobulins, OCBs may suggest a pathogenic role that autoreactive antigen-specific B
cells play in MS. The presence of OCBs is a valuable tool in confirmation of MS diagnosis.47–49
However, having no or little variability with disease activity or clinical disability, OCBs have little
utility as a biomarker in clinical treatment trials.
Previous studies have assessed molecules for their
ability to diagnose MS or provide predictive data.
However, aside from recent novel observations
on serum neurofilament light chain levels as a
marker of disease activity and a tool to monitor
treatment responses,50,51 most other biomarkers
that have been studied lack sensitivity, specificity,
and predictive value.44
Current problems with trial design in MS
Given the heterogeneity and diagnostic methods
of MS, extensive clinical trial programs that entail
very large numbers of patients and long durations
are needed for each new agent to be tested and
approved. In addition, with the availability of
already-approved effective treatments, active
comparator-controlled trial designs are now commonly employed, resulting in the need to recruit
even larger cohorts with longer follow-up periods
per trial than placebo-controlled studies before
meaningful clinical and statistical differences can
be reliably detected. As mentioned above, another
issue is the lack of sensitivity and utility of presently employed clinical and paraclinical assessments, which contributes to needing large
numbers of patients and long-duration clinical
trials in MS.
journals.sagepub.com/home/tan

Clinically, and presumably pathogenetically, diverse
patient populations are recruited to current MS
clinical trials based on standard inclusion and exclusion criteria. Consequently, negative or positive
results may be driven by a particular subgroup, as
suggested by post-hoc analyses.52,53 Nonresponders
in study cohorts not only fail to receive the benefits
of therapeutic interventions, but they also dilute
positive signals from the responders in their cohort.
Furthermore, data obtained from these studies are
utilized to identify active comparator controls for
future trials. Therefore, any bias from unrecognized effects of nonresponders on clinical trial outcomes often carry over to future assessments of
novel therapies.
Finally, all investigations of new therapies are
accompanied by a burden of risk for the study participants through unexpected adverse reactions, or
through the substantial delay in drug approval
that may result from the current trial designs.
Requirements for novel trial designs
First, tangible goals should be articulated that
allow the identification of well-defined study populations and treatment responders through biological markers. These markers should allow the
identification of likely treatment responders and
nonresponders within clinical trial cohorts, and
the verification of a response and nonresponse in
validation cohorts. Such markers can be viewed
as dynamic and sensitive surveillance methods
that allow detection of positive response to DMTs
in a given patient. Currently available examples
include the visualization of MRI brain lesions and
the quantification of cerebrospinal fluid (CSF)
and blood neurofilament by digital enzyme-linked
immunosorbent assay (ELISA).
Safety and effectiveness are the two main deliverables of the clinical trials process. Pharmacological
safety is relatively easily defined by the incidence of
adverse effects and side-effects of a therapeutic
intervention. The remainder of this article focuses
on the definition of effectiveness, which is considerably more challenging in MS.
To achieve approval of therapeutic interventions
that are ideally suited for a defined patient population, the goals should be the identification of
biological markers that predict a meaningful clinical response to each pharmacological agent in
patient subgroups, to reduce the sample size of
3
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the study population, to shorten the duration of
the clinical trial, and to accelerate drug approval.
Ideally, investigators will be able to group MS
patients into objectively differentiable subclasses
through these biological markers. Admittedly,
this is a tall order in the face of the many treatments available, and the lack of modern natural
history data.
Novel candidates for MS biomarkers should meet
the following criteria before they can achieve any
advantage over current methods. A potential candidate biomarker should (1) reflect the underlying pathophysiology of MS; (2) differentiate
sensitively between the disease phenotypes in a
prospective assessment of MS populations; (3)
detect disease reactivation; and (4) provide reliable data for a precise prediction of disease severity
and prognosis. These criteria are difficult, but
achievable, goals.
Endophenotypes in MS classification
Endophenotypes refer to subclasses present
within one clinical diagnosis.54 They have various
manifestations that are linked to underlying
genetic and epigenetic differences between individuals.55 However, their divergence never
exceeds the definitions of the background clinical
syndrome. Since they are rooted in the genetic
variations, endophenotypes are inheritable. Their
effects are reflected through a matrix of biochemical molecules that are made or adjusted based on
the genetic code. Biomarkers, defined as an objectively measurable feature that differentiates
between normal and pathologic states and
responds to therapeutic interventions,56 are suitable candidates for (1) the disease diagnosis and
(2) the identification of endophenotypes in disease populations. Such endophenotypes are represented through a meaningful shift in biomarkers
compared with other disease subclasses that
allows for disease monitoring.
The majority of previous biomarker studies in
MS was hypothesis-driven and focused on the
associations of MS clinical phenotypes with single
biomarkers. In some instances, studies with wider
scopes were able to draw conclusions from shifts
in patterns of large biomarker groups within individual MS patients or across MS populations.57
The multifactorial and complex pathogenesis of
MS likely causes variable changes across a wide
4

field of interdependent biomarkers that amount to
system-level cascades of biochemical rearrangements. Thus, implementation of a reductionist
approach based on genomic and proteomic analysis of biomarkers where type and number of measured variables are limited only by the overall power
of the final model should be utilized to define
objective MS endophenotypes. In this article, we
utilize the term ‘disease classifying biomarkers’
(DCB) as a representation of a multivariable model
based on multiple genomic and proteomic measurements of biomarkers in MS biological samples.
Through novel proteomics assays, biomarkerbased categorization of MS subclasses suggest (1)
stable intraindividual levels of MS-related biomarkers in steady states; (2) meaningful differences in biomarker levels between healthy
populations and MS patients; (3) variations in
biomarker levels and ratios across different MS
subclasses; and (4) an active response to MS progression and therapeutic interventions.57 These
methods are still limited due to the noise that is
inherent to spectroscopic prote-omics assessments. In particular, the biomarker discovery
phase often suffers from overfitting, meaning
small samples on which a high number of tests is
being conducted, and often without correction
for multiple comparisons. These new strategies
should be verified in controlled prospective validation studies.57,58
Prospective cohorts for endophenotype
validations
The implementation of DCB-based endophenotype definition in MS classification is the primary requirement for the improvement of future
MS trials. A variable disease spectrum is also
likely with biomarker-based endophenotypes.
For a new DCB-based MS disease spectrum to
have any clinical significance, validation studies
have to be undertaken to establish treatment
response rates of patients within each endophenotype across the whole spectrum. Measuring
DCBs through extensive -omics studies in
patients with proven response to certain DMTs
across the entire range of MS phenotypes determines the distribution of specific DCBs for each
part of the disease spectrum. We hypothesize
that suitable DCBs yield measurable predictions in terms of prognosis and response to their
corresponding treatments. Such predictions will
require validation through demonstrable
journals.sagepub.com/home/tan
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Figure 1. The definition of multiple sclerosis (MS) endophenotypes (EPs) will be based on response to
disease-modifying therapies (DMTs) in prospective validating cohorts. Disease classifying biomarkers
(DCBs) constitute the most reliable multivariate model recognizable from biomarker portfolios in each MS
subpopulation. The implementation of new endophenotypes translates the current clinical and paraclinical
subtypes of MS into finite biomarker-based MS endophenotypes.

correlations with MRI imaging outcomes and
dynamic and sensitive disease markers, such as
CSF and blood neurofilament levels in relatively
short prospective studies among age- and
comorbidity-adjusted patient cohorts. This will
be a dynamic process that adds validated DCBs
which, once validated, may replace their MRI
and clinical assessment predecessors in future
trial designs (Figure 1). Furthermore, in prospective cohort studies treatment response data
of each DMT can be analyzed against endophenotype subpopulations. By using the already
established DCBs, current DMTs with the most
effectiveness for each endophenotype will be
determined (Figure 2).
Novel MS trial design
Prospective validation of DCB-based MS endophenotypes in terms of treatment responses will
allow new trial designs. This new concept would
be especially useful in phase III trial designs where
objective effectiveness benefits of novel therapies
are weighed against currently approved DMTs.
However, there needs to be some precautions and
guidelines to consider in a DCB-based trial
design. Simon and Maitournam’s discussion of
targeted trial design points out that many factors
journals.sagepub.com/home/tan

impact the success for targeted designs, which fall
under the rubric of precision medicine.59 First is
the proportion of responsive patients, the accuracy of the assay identifying the targeted group,
and the degree to which the mechanism of action
is understood. They point out that when the
group that tests positive for the biomarker is over
50% of the population, the value of the targeted
design is minimal, and the costs of screening and
recruitment can outweigh any benefits. Similarly,
unless there is marked differences in responsiveness between those with and without the biomarker, the targeted design may not be efficient
since the larger sample size can overcome the
mixing of the benefits between those with and
without the biomarker by eliminating the need to
screen and only randomize those with the
biomarker.
Study goals: primary outcome measures
The study goals, as in any other new MS treatment trial, should be the reduction or complete
suppression of disease activity and the prevention
and/or minimization of neurological deficit accumulation in the shortest possible time span. In
comparison with current outcome measures in
MS trials, where studies look for relapse rate
5
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Figure 2. Endophenotype (EP)-based therapeutic interventions are most effective within their corresponding
multiple sclerosis (MS) endophenotype.

reduction, slowed disability worsening, stabilization, or improvement, and a decrease in the number of brain MRI lesions and global or regional
atrophy, biomarker-based outcomes could arrive
at the same conclusion faster and with more
reproducible results.
DCBs for each endophenotype will be used for
establishment of effectiveness in comparison with
previously available effective DMTs for the same
endophenotype. The nature of direct measurements of biomarkers provides a faster registration
of response to treatment, but at the same time the
additive power of measuring multiple biomarker
variables in DCB models can be harnessed to
arrive at a definitive conclusion of study outcomes
in significantly less time compared with current
designs.
This may afford what are called basket and
bucket trials, where one mutation or molecular
variation is studied with multiple drugs or one
drug is applied to multiple mutations or molecular variations. These trials may allow various
approaches to treatment trials where multiple
component trials are ongoing with the same
infrastructure and same measurements, but the
outcomes may differ, and/or the drugs and treatments may differ.
6

Controls: randomization
Each new DMT will go through phase I and II
trials where the most eligible endophenotypes for
the new treatment are determined, before it is
assessed in a phase III trial. Recruited control
patients, randomized into an active comparator
group, will also be selected from the same endophenotypes. An enrichment trial design with
noninferiority control model might be used to
determine the effectiveness of the experimental
treatment against a control population with the
same disease endophenotype receiving the best
alternative DMT evident by DCB responses
(Figure 3). Alternatively, multiple treatments
may be compared, dropping inferior treatments
as they are identified with comparisons with
cohorts of controls in what are called platform
trials. Platform trials use a single protocol with
multiple treatments evaluated. Adaptive platform trials allow for dropping treatments for
futility, superiority, or adding new treatments to
be tested. They require extensive planning and
cooperation on the part of the treatment providers, especially pharmaceutical companies who
may feel they have too much at risk to participate. These approaches are admittedly novel in
the field of MS. However, similar designs have
been successfully implemented in other areas of
clinical medicine, including oncology trials. The
journals.sagepub.com/home/tan
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Figure 3. New endophenotype (EP)-based multiple sclerosis (MS) trial design versus the status quo.
Following an enrichment trial design, new disease-modifying therapies (DMTs) will be assessed against intraendophenotype patient-DMT controls.

similarities of a DCB-based definition of endophenotypes in MS to mutation-based models of
cancer categorization provide plausibility for
their potential success in MS. Very likely, DCBbased MS endophenotypes will be inherently different from the strictly genetic basis of cancer
subpopulations.60–62
Sampling population: sample size
The lowest number of inclusion criteria will allow
more applicable or pragmatic clinical trials and
will achieve the greatest generalizability. However,
patient enrollment should include individuals
with similar endophenotypes who will be identified at a screening DCB evaluation. To avoid
confounding by prior treatment, it is ideal to have
treatment-naïve patients with the desirable endophenotypes randomly assigned to the experimental treatment group or an active comparator
control. Since the DCB-based endophenotypes
are reactive to DMT, biomarker-washout process
should be validated for each DMT in comparison
with treatment-naïve patients prior to study
enrollments.
Selecting patients from within one endophenotype homogenizes the samples in the experimental treatment and control groups, reducing the
variability among patients and thus allowing for
detection of treatment differences with smaller
sample sizes.

journals.sagepub.com/home/tan

Furthermore, the shift from clinical outcome
measures toward DCB-based assessments changes
the framework of the minimum accepted changes
for a clinical significance: The new variables will
have considerably wider ranges resulting in a significant drop in the required sample size. The
combined effects of these two factors are potentially strong enough to decrease the number of
enrolled patients in the new trials. In current trial
settings for MS, the heterogeneity of the patient
population and DMT responses invokes the need
for sample sizes of over 1000 patients. The hope
with employing an endophenotype-based trial
approach is to substantially diminish the number
of patients that need to be enrolled to show a beneficial effect of a therapeutic intervention.
Another factor that needs to be considered is the
time to events or changes of interest. Even biomarkers that are responsive and predictive may
take some time to validate, optimize the timing of
assessment, and/or even understand within the
context of a statistical design, and thus affect the
sample size.
Generalizability of the outcome
The final results of the study will be generalizable
to all MS patients within the same endophenotype subclass that participated in the trial. As was
noted above, this may depend on the homogeneity of prior therapy, if any, and other factors that

7
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may coexist with these endophenotypes. However,
it will be of critical importance that enrolled
patients in the experimental treatment group or
controls are of similar age, gender, and preexisting comorbidities, for example, since these factors
potentially confound biomarker-based readings
through their effects on biochemical properties.
The use of randomization produces comparable
groups in the long run, but the reduction of sample sizes may also result in greater natural variability. This may lead to matching and/or stratifying
and should be taken into account in the analyses.
By using similar endophenotypes, one might
expect that the ‘nonresponder effect’ on the
results will also be diminished, which provides
greater reliability regarding other, similar study
populations. DCB-based endophenotypes will
likely be dynamic due to the administration of
therapeutic agents and their potential effects on
biomarkers, and due to the natural progression of
the disease with changes in its biology. These
changes could potentially move individual
patients between endophenotypes. It will likely be
necessary that treatment strategies and trial planning be tailored to patients over time and to assess
the impact of these changes. A longer duration of
clinical trials may increase the chance of such
endophenotype changes.
Conclusion
Despite the progress that has been made in the
field of MS therapeutics through the development
and clinical testing of DMTs, the already heterogeneous MS population is further diversified
through variable responsiveness to individual
DMTs. Any novel and more effective DMT
requires a significant superiority over previous
treatments established through rigorous trials.
However, treatments that may have specific effects
that are of value over the long term may be missed
by an aggregate result that looks like other standard therapies. An objectively universal measure
will be required to be incorporated into the future
MS trials that categorizes MS patients into homogenous subclasses. The hope of this approach is that
statistical and clinical significance of clinical trials
will be improved. A biomarker-based model of
endophenotyping in MS populations using compound genomics and proteomics patterns should
provide a basis for faster and more reliable trial
designs in MS populations. Studies for biomarkerbased models of endophenotyping in MS and
8

validation studies required for utilization of such
models in research should be considered a priority
in MS research.
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